semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Neck Pain Cervical Pain years old and over Medical diagnosis of chronic cervical pain (more than 3 months of cervical pain evolution) Positive flexion rotation test  Recent spine, head or mouth surgery Diabetes mellitus Recent infection and/or inflammatory arthritis, and cervical and/or brain traumatism records Contraindication for manual therapy or cervical training
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 6.0-12.0,  Closed Loop Diabetes Mellitus, Type 1 Young Children (6 to 12 Years Old ) Prepubescent children (Gender: both) aged between 6 to 12 years old (Tanner stage 1) at time of screening Type 1 diabetes as defined by WHO for at least 1 year or confirmed C peptide negative An insulin pump user for at least 3 months Subject having a Glycosylated hemoglobin (HbA1c) blood value < 9% at time of screening visit-based on analysis from local laboratory within 3 months Subject having a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units Subject and his parent/guardian willing to spend 3-overnight in hospital Subject willing to wear the system continuously throughout the study Subjects and his parent/guardian must be able to speak and be literate in French or Flemish as verified by the investigator  Children who are in pubertal stage Subject has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening Medical assistance (i.e. Paramedics, Emergency Room (ER) or Hospitalization) Coma Seizures Subject having sever DKA in the 6 months prior to screening visit Known or suspected allergy against insulin Any other physical or psychological disease, or medication likely to interfere with the conduct of the study and interpretation of the study results as judged by the investigator Subject is unable to tolerate tape adhesive around the sensor or pump placements Subject has a cardiovascular condition which the investigator determines should the subject, i.e. ventricular rhythm disturbance, hypertrophic cardiomyopathy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Reconstructive Surgery After Carcinological Excision Patient eligible for reconstructive surgery after carcinological excision following a decision taken in a multidisciplinary consultation, and for whom the envisaged oral defect concerns either the soft tissues of the oral cavity and oropharynx, or the mandibular bone Scheduled post-operative radiotherapy Coverage by the Social Security system Capacity to provide informed consent  Post-traumatic substance loss (ballistic autolysis) Surgical or anesthetic contraindication (physiological age, other proposed therapeutic options) Pregnant or breastfeeding woman Subject incapable of full age or deprived of liberty Indication for chemotherapy with highly neurotoxic agents Inability to complete questionnaires or express feelings during the examination Any situation judged by the investigator as a contraindication to neurorrhaphy
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-80.0,  Osteo Arthritis Knee Knee Arthroplasty patients scheduled for unilateral TKA secondary to osteoarthritis age from 50 to 80 years old participants were not engaged in preoperative treatments  participants who were undergoing a revision TKA body mass index (BMI) greater than 40 kg/m2 participants who were receiving a bilateral TKA's uncontrolled hypertension diabetes mellitus a history of any neurological disorder multiple sclerosis Parkinson's disease patients with rheumatoid arthritis or active cancer previous history of deep vein thrombosis
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 7.0-7.0,  Typical Development Risk of Dysgraphia Dysgraphia Children in the second grade (aged 7 years old) Participation agreement  Diagnosed or suspected of neurological disabilities (e.g., cerebral palsy, epilepsy), psychiatric and/or behavioural disorders Presence of uncorrected vision and hearing problems Referenced by Special Education/National Service of Early Intervention in Childhood Presence of one or more school retentions Native language is not Portuguese Children with direct intervention in graphomotor skills or who had a similar intervention to that proposed less than 1 year ago Participation in the intervention program of less than 80% Children undergoing drug therapy (e.g., antihistamines) that interfere with the study variables Do not wish to participate in the study
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Parkinson's Disease Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic criteria Parkinson's disease patients in Stages 2 to 4 on the Modified Hoehn and Yahr Scale. (mH&Y, Evaluation at ON state for patients who experience Wearing-off phenomenon) MDS-UPDRS partIII score of >= 15. (Evaluation at ON state) Subject who are responsive to levodopa/DCI (carbidopa or benserazide) combination therapy and who have been on the therapy for 6 months or longer without interruption at enrollment Subject who have not started any new antiparkinsonian drugs and have been on a stable regimen of antiparkinsonian drugs in the 3 months before enrollment  Use of any CYP3A4/5-related drugs within 2 weeks prior to enrollment Use of any of the following drugs within 3 months (or 6 month in case of depot preparations) prior to enrollment; Antipsychotics, tiapride, metoclopramide, amoxapine, reserpine, tetrabenazine, methyldopa, papaverine, Levodopa/carbidopa intestinal gel and apomorphine hydrochloride injection Treatment by transcranial magnetic stimulation (TMS) within 6 months prior to enrollment Neurosurgical operation for Parkinson's disease. (stereotactic surgery, deep brain stimulation or gamma knife) Subject who have received administration of adenosine A2A receptor antagonist Either of the following consecutively at screening and enrollment; Resting Pulse > 100 bpm Resting systolic blood pressure > 140 mmHg, or diastolic blood pressure > 90 mmHg Significant dementia or a Mini-Mental State Examination (MMSE) score of =< 23 Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating Scale (C-SSRS) at baseline Anyone otherwise considered unsuitable for the study by the investigator or subinvestigator including those who are unable to communicate or to cooperate with the investigator or subinvestigator
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-80.0,  Parkinson Disease Movement Disorders Men and women between the ages of 40 and 80 years Diagnosis of idiopathic Parkinson's disease based on the UK PD Brain Bank criteria35 PD diagnosis within 5 years (≤ 5 years) Hoehn and Yahr severity stage less than or equal to 3 (Mild to moderate bilateral disease; some postural instability; physically independent).36 Remain untreated with levodopa or a dopamine agonist for the duration of the study (up to 7 months, can have treatment with MAO-B inhibitors rasagiline or selegiline) Able to understand and give informed consent for the study Able to stand and walk unassisted  Current use of dopamine-blocking therapy or significant history of dopamine-blocking therapy (> 1 yr of daily use of the following: typical and atypical antipsychotics except for quetiapine and clozapine, metoclopramide, prochlorperazine, tetrabenazine, reserpine) Autoimmune disease or current anti-inflammatory or immunomodulatory therapy (aspirin, Tylenol, ibuprofen, naproxen OK) Other condition already causing gait dysfunction or likely to cause significant change in motor/gait function over 6 month period (i.e. knee or hip replacement within the past 6 months or surgery planned during the study, peripheral neuropathy causing impaired proprioception at big toes) History of treatment with carbidopa/levodopa, dopamine agonist, or amantadine (can have history of treatment with MAO-B inhibitors rasagiline or selegiline) Patient anticipates that they will require symptomatic treatment for PD within the next 6 months
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cirrhosis for EHM+ subjects Age between 18 and 70 (inclusive) Cirrhosis Minimal hepatic encephalopathy Expression of non opposition for EHM subjects Age between 18 and 70 (inclusive) Cirrhosis No hepatic encephalopathy (minimal or clinical) Paired with EHM+ subjects about age, gender, MELD score and cirrhosis etiology  for all subjects Age older than 70 MMS score < 24 Clinical hepatic encephalopathy Cirrhosis etiology different from alcoholic, viral or metabolic one Intake of psychotropic drugs within 48h Alcohol intake > 30 g/j Heart, renal or respiratory failure Evolutive neurological diseases History of neurological diseases causing consequences
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Patients aged ≥ 18 years Patients affected by Parkinson's disease (PD) according to the diagnostic of the United Kingdom Brain Bank, in the ON phase of their usual treatment Hoehn-Yahr Stage from 1 to 3 Signature of the Informed Consent and of the privacy form  Patients with symptoms and signs compatible with atypical parkinsonism PD patients treated with antagonist drugs for central dopaminergic receptors (first and second generation antipsychotics) in the last 6 months before enrollment Patients suffering from other neurological diseases Patients with evident cognitive impairment (MMSE <24/30) Patients with manifest eye movement disorders prior to the diagnosis of PD Patients with daltonism Patients with amblyopia Patients suffering from high anisometropia Patients suffering from advanced cataracts Patients suffering from glaucoma
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypertension Cardiovascular Diseases Vascular Diseases BP>=140/90 and <=180/110 mm Hg at time of discharge from ED Verbal fluency in English or Spanish Age 18-75 years  Unable to verbalize comprehension of study, impaired decision-making or documented dementia Plans to move from Chicago area within the next year Pregnant or trying to get pregnant
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Liver Failure as A Complication of Care Patients subjected for major liver surgery (4 or more Couinaud segments) or patients undergoing a 2nd, 3rd or 4th hepatic resection. Pre-operative chemotherapy and/or biological agents are allowed Primary PHLF occurring early after surgery defined by the 50:50 (from PO day 5 to day 14) or by the presence of hepatic encephalopathy grade 2 or more and the 50:50 (from PO day 3 to 4) Written informed consent  ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy) procedure In patients with chronic liver disease presence of significant portal hypertension (hepatic venous pressure gradient ≥ 10 mmHg and/or Fibroscan ≥ 21kPa) prior to surgical intervention Any contraindication for MARS therapy such as uncontrolled active bleeding, platelet counts <20.000 /µl or uncontrolled infection (presence of fever or adequate antibiotic therapy for less than 48h), septic shock, haemodynamic instability requiring inotropic support (noradrenaline > 1mg/h) PHLF occurring after post operative day 14 Secondary PHLF: post-operative liver failure secondary to vascular (outflow or inflow thrombosis) or septic problems Persistant biliary complications (infected biloma, main biliary tree damage) Inability or unwilling of the patient or family to give informed consent
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 8.0-75.0,  Dietary Habits Health Behavior Eating Behavior Children ages 8-12 Adults ages 21-75 Elementary schools in Tsaile and Shiprock will have been in existence for at least three years, school size (have between 40 to 100 students in grades 3 and 4 combined), have more than two-thirds Navajo students and satisfy a garden site checklist that can overcome garden barriers (e.9. have access to water) Assessment is restricted to Male/female students in grades 3 and 4 attending, attending school in either Tsaile or Shiprock and one family member (Navajo adult aged 18 and older) for each child  Family member child dyads neither of which are Navajo Family member/child dyads not expected to stay at the recruited Tsaile or Shiprock elementary school for the whole school year
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Patients having Parkinson's disease according to United Kingdom Parkinson's Disease Society Brain Bank (UKPDSBB) All Parkinson's patients presenting motor fluctuations and/or disabling dyskinesia and in need of the establishment of a second line treatment by subcutaneous apomorphine infusion or intrajejunal infusion of levodopa-carbidopa in the context of classical care of their Parkinson's disease Patient able to give its free and informed consent Patient having a social security  Patients presenting atypical Parkinson's syndrome Patients having a deep brain stimulation Patient having a psychiatric disease such as: mood disorders, psychotic disorder… Patients presenting a cognitive decline evaluated by a Montreal Cognitive Assessment (MoCA) score inferior to 24 None ability to give its consent Patients unable to realize the tests provided in the context of this study Patients under supervision, curators, or legal guardian Patients non-affiliated to a social security Patients in period of another study